Skip to main content

Advertisement

SpringerLink
Log in

Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

More than half of melanoma patients taking first-line anti-PD-1 therapy either express transient or no response at all. The efficacy and safety of secondary treatments for these patients are still not well established. Here, we evaluate the efficacy and safety of different melanoma FDA-approved ICI modalities used in post-anti-PD-1 refractory settings.

Materials and methods

We searched the PubMed database and the ASCO meetings library for studies on advanced melanoma patients with cancer progression on anti-PD-1 therapy and were then treated with ipilimumab, nivolumab/ipilimumab combination, or retreated with anti-PD-1. Primary and secondary endpoints were efficacy and toxicity, respectively. Pooled estimates for each treatment group were obtained using a random or fixed effects model according to detected heterogeneity.

Results

Fourteen studies, of which 10 on ipilimumab, 2 on anti-PD-1 treatment, and 6 on combination therapies, were included, involving a total of 1460 patients. Twelve studies reported objective response rates (ORRs) and nine of them reported immune-related adverse events (irAEs). As for ORR, patients experienced a response that was inferior compared to the same therapy in treatment -naïve patients, with combination therapy having the best ORR of a pooled 23.08% (95% CI: 16.75% to 30.03%), followed by ipilimumab with a pooled ORR of 8.19% (95% CI: 5.78% to 10.92%). Survival data were also inferior in the ipilimumab cohort (mOS: 5.1 to 7.4 months) compared to ipilimumab in anti-PD-1 naive patients. As for grade 3/4 irAE occurrence, the ipilimumab cohort showed an estimate of 43.77% (95% CI 22.55% to 66.19%).

Conclusion

Our findings provide the best current evidence that patients who progress on anti-PD-1 can still respond to different ICI modalities (ipilimumab with or without nivolumab, and retreatment or continuation beyond progression with anti-PD-1) with tolerable grade 3/4 irAEs. However, more prospective clinical trials are needed to confirm these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Code availability

Not applicable.

References

  1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  PubMed  Google Scholar 

  2. recent progress and potential biomarkers. Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors. Exp Mol Med. 2018;50:1–11.

    Google Scholar 

  3. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.

    Article  CAS  PubMed  Google Scholar 

  5. Wróbel S, Przybyło M, Stępień E. The clinical trial landscape for melanoma therapies. J Clin Med. 2019;8:368.

    Article  PubMed Central  CAS  Google Scholar 

  6. Opdivo-Yervoy Combination Approved for Melanoma. First Combination-Immunotherapy Regimen for Cancer. Oncol Times. 2015;37:39.

    Google Scholar 

  7. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–86.

    Article  PubMed  Google Scholar 

  8. Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239–51.

    Article  CAS  PubMed  Google Scholar 

  9. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24:1260–70.

    Article  CAS  Google Scholar 

  11. Babacan NA, Eroglu Z. Treatment options for advanced melanoma after anti-PD-1 therapy. Curr Oncol Rep. 2020;22:38.

    Article  CAS  PubMed  Google Scholar 

  12. Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (London, England). 2014;384:1109–17.

    Article  CAS  Google Scholar 

  13. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet (London, England). 2017;390:1853–62.

    Article  CAS  Google Scholar 

  14. Network, N. C. C. Cutaneous Melanoma (Version 4.2020). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf (2020).

  15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

    Article  PubMed  PubMed Central  Google Scholar 

  16. GA Wells, B Shea, D O’Connell, J Peterson, V Welch, M Losos, P. T. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

  17. Schwartz LH, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132–7.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Somarouthu B, et al. Immune-related tumour response assessment criteria: a comprehensive review. Br J Radiol. 2018;91:20170457.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Institute, N. C. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (2017).

  20. Campbell M, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Team, R. C. R: A Language and Environment for Statistical Computing. (2013).

  22. Sterne JAC, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.

    Article  PubMed  Google Scholar 

  23. Betof Warner A, et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:1655–63.

    Article  CAS  Google Scholar 

  24. Zimmer L, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017;75:47–55.

    Article  CAS  PubMed  Google Scholar 

  25. Bowyer S, et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer. 2016;114:1084–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cybulska-Stopa B, et al. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients—real world evidence. Adv Med Sci. 2020;65:316–23.

    Article  PubMed  Google Scholar 

  27. Tsutsumida A, et al. Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma. J Dermatol. 2019;46:947–55.

    Article  CAS  PubMed  Google Scholar 

  28. Fujisawa Y, et al. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients. J Dermatol Sci. 2018;89:60–6.

    Article  CAS  PubMed  Google Scholar 

  29. Muto Y, et al. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. J Dermatol. 2019;46:498–506.

    Article  CAS  PubMed  Google Scholar 

  30. Baron K, et al. Comparative effectiveness of second-line ipilimumab vs nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2020. https://doi.org/10.1177/1078155220924719.

    Article  Google Scholar 

  31. Mehmi I, Hill J. Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma. J Clin Oncol. 2018;36:e21552–e21552.

    Article  Google Scholar 

  32. Prithviraj P, et al. Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy. J Immunother Cancer. 2015;3:P126–P126.

    Article  PubMed Central  Google Scholar 

  33. Weichenthal M, et al. Salvage therapy after failure from anti-PD-1 single agent treatment: a Study by the German ADOReg melanoma registry. J Clin Oncol. 2019;37:9505.

    Article  Google Scholar 

  34. Olson D, et al. Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel). J Clin Oncol. 2018;36:9514.

    Article  Google Scholar 

  35. Long, G. V. et al. Outcomes in patients (pts) treated with ipilimumab (ipi) after pembrolizumab (pembro) in KEYNOTE-006. in Society of Melanoma Research 2016 Congress. (2016).

  36. Beaver JA, et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2018;19:229–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Hodi FS, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480–92.

    Article  CAS  PubMed  Google Scholar 

  38. Mignard X, et al. Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer? Bull Cancer. 2019;106:725–33.

    Article  PubMed  Google Scholar 

  39. Tahara M, et al. Re-challenge of platinum-based chemotherapy for platinum-refractory patients with recurrent or metastatic head and neck cancer: claims data analysis in Japan. J Heal Econ outcomes Res. 2020;7:43–51.

    Article  Google Scholar 

  40. Cho J, et al. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Invest New Drugs. 2016;34:677–84.

    Article  CAS  PubMed  Google Scholar 

  41. D’Angelo SP, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:226–35.

    Article  Google Scholar 

  42. Fujisawa Y, et al. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med. 2019;8:2146–56.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Thierauf J, et al. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res. 2015;25:503–9.

    Article  CAS  PubMed  Google Scholar 

  44. Duyx B, Swaen GMH, Urlings MJE, Bouter LM, Zeegers MP. The strong focus on positive results in abstracts may cause bias in systematic reviews: a case study on abstract reporting bias. Syst Rev. 2019;8:174.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Larkin J, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.

    Article  CAS  PubMed  Google Scholar 

  46. Hodi FS, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1510–7.

    Article  CAS  Google Scholar 

  47. Gobbini E, et al. Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients. Bull Cancer. 2020. https://doi.org/10.1016/j.bulcan.2020.07.009.

    Article  PubMed  Google Scholar 

  48. Brahmer JR, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3167–75.

    Article  CAS  Google Scholar 

  49. Sade-Feldman M, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019;176:404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Sade-Feldman M, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8:1136.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ramos RN, Piaggio E, Romano E. Mechanisms of resistance to immune checkpoint antibodies BT—mechanisms of drug resistance in cancer therapy. In: Mandalà M, Romano E, editors. pp 109–128. New York: Springer; 2018. https://doi.org/10.1007/164_2017_11.

    Chapter  Google Scholar 

  53. Chowell D, et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019;25:1715–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Montesion M, et al. Somatic HLA class I Loss Is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 2021;11:282–92.

    Article  CAS  PubMed  Google Scholar 

  55. Haanen J, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer. 2020;8:e000604.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Pollack MH, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:250–5.

    Article  CAS  Google Scholar 

  57. Wang DY, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721–8.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Simonaggio A, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 2019;5:1310–7.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Reschke R, Ziemer M. Rechallenge with checkpoint inhibitors in metastatic melanoma. JDDG J der Dtsch Dermatologischen Gesellschaft. 2020;18:429–36.

    Google Scholar 

  60. Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist. 2017;22:81–8.

    Article  CAS  PubMed  Google Scholar 

  61. Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2015;7:365–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Sternschuss M, et al. Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents? Thorac cancer. 2020;11:2331–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Escudier B, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in checkmate 025. Eur Urol. 2017;72:368–76.

    Article  CAS  PubMed  Google Scholar 

  64. Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer. 2020;11:1927–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Johnson DB, et al. Sequencing treatment in BRAFV600 mutant melanoma: anti-PD-1 before and after BRAF inhibition. J Immunother. 2017;40:31–5.

    Article  CAS  PubMed  Google Scholar 

  66. Dafni U, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:1902–13.

    Article  CAS  Google Scholar 

  67. Vera Aguilera J, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020;30:364–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Hadash-Bengad R, et al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma—a retrospective study. Front Oncol. 2020;10:70.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Park SE, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 Inhibitors in patients with non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13:106–11.

    CAS  Google Scholar 

  70. Saleh K, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2019;121:123–9.

    Article  CAS  PubMed  Google Scholar 

  71. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21:15–25.

    Article  CAS  PubMed  Google Scholar 

  72. Chesney J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1658–67.

    Article  CAS  Google Scholar 

  73. Ascierto PA, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J Clin Oncol. 2017;35:9520.

    Article  Google Scholar 

  74. Schadendorf D, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1889–94.

    Article  CAS  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan

    N. N. Alrabadi

  2. Facullty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan

    H. M. Abushukair, O. E. Ababneh, S. S. Syaj, S. S. Al-Horani, A. A. Qarqash, O. A. Darabseh, M. M. Al-Sous, S. R. Al-Aomar & Y.. B. Ahmed

  3. Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan

    R. Haddad

  4. Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan

    F. A. Al Qarqaz

Authors
  1. N. N. Alrabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. M. Abushukair
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. E. Ababneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. S. Syaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. S. Al-Horani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. A. Qarqash
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O. A. Darabseh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. M. Al-Sous
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. R. Al-Aomar
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Y.. B. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. Haddad
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F. A. Al Qarqaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: HMA, NA.Literature search: HMA, OEA, MMAS, SRA-A, NA. Data extraction and analysis: SSS, SSA-H, AAQ, NA. Quality assessment of included studies: OAD, OEA, NA. Manuscript writing: YBA, HMA, OEA, NA. Critical revision: FAAQ, NA, RH.

Corresponding author

Correspondence to N. N. Alrabadi.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest or competing interests.

Ethical approval

Not applicable.

Informed consent

This is a systematic review and meta-analysis article which doesn’t need informed consent or any ethical approvals in its current form.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Electronic supplementary material 1 (DOCX 1966 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alrabadi, N.N., Abushukair, H.M., Ababneh, O.E. et al. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. Clin Transl Oncol 23, 1885–1904 (2021). https://doi.org/10.1007/s12094-021-02598-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02598-6

Keywords

Search

Navigation